No abstract available
Keywords:
T-DM1; cost-effectiveness analysis; metastatic breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Ado-Trastuzumab Emtansine
-
Antineoplastic Agents* / therapeutic use
-
Breast Neoplasms* / drug therapy
-
Cost-Benefit Analysis
-
Female
-
Humans
-
Receptor, ErbB-2
-
Taiwan
-
Trastuzumab / therapeutic use
Substances
-
Antineoplastic Agents
-
Receptor, ErbB-2
-
Trastuzumab
-
Ado-Trastuzumab Emtansine